IDH1 and central nervous system cancer: Yang et al. reported that inhibiting F-box and WD repeat domain containing 7 (FBXW7) in glioma cells could enhance the expression of wild-type and mutant isocitrate dehydrogenase 1 (IDH1) through stabilizing sterol regulatory element binding protein 1 (SREBP1), which leads to significant enhancement in the NADPH-consuming 2-hydroxyglutarate synthesis activities and thus deplete NADPH pool in glioma cells, eventually disrupting the redox homeostasis and sensitizing glioma cells for radiotherapy-induced apoptosis 122.